HHS Will Not Use March-In Rights For Remdesivir

By Ariel Cohen / August 17, 2020 at 4:32 PM
The administration says it will only use march-in rights to lower the cost of COVID-19 drugs if all a product’s patents are owned by the federal government, which is not the case for remdesivir. The administration’s stance is in direct opposition to that of a bipartisan group of 34 state attorneys general that recently called on the government to either use its march-in rights or allow states to sidestep patents to lower the cost of the antiviral, which hospitals are...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.